MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 17, 2005; DOI: 10.1124/mol.105.020727


0026-895X/06/6902-407-410$20.00
Mol Pharmacol 69:407-410, 2006

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.105.020727v1
69/2/407    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, M. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYSTEINE
Perspective

Pretty Subunits All in a Row: Using Concatenated Subunit Constructs to Force the Expression of Receptors with Defined Subunit Stoichiometry and Spatial Arrangement

Michael M. White

Department of Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania

Received for publication November 10, 2005.

Accepted for publication November 17, 2005.


    Abstract
 Top
 Abstract
 References
 
The members of the Cys-loop ligand-gated ion channel (LGIC) gene family play a major role in fast synaptic transmission, and these receptors represent an important class of targets for therapeutic agents. Each member of this gene family is a pentameric complex containing one or more different subunits, and a large number of subunits for each member have been identified. This large number of subunits could give rise to a bewildering array of possible subunit compositions and spatial arrangements within a single complex, not all of which may occur in vivo. Heterologous expression systems have been used to create specific combinations of individual subunits to mimic naturally occurring receptors. However, this approach is not without its problems. In this issue of Molecular Pharmacology, Groot-Kormelink et al. (page 559) describe a method for constructing "concatameric" receptors, in which five individual subunits are arranged in a predetermined order connected by a flexible linker. Expression of this construct results in the formation of receptors with a unique, predefined subunit stoichiometry and subunit arrangement within the receptor complex. Receptors formed from this construct are fully functional and have properties essentially identical to those formed from individual subunits. The application of this very general approach to other members of the LGIC family should markedly enhance our ability to understand how subunit composition influences receptor function, as well as provide a means for the expression of receptors of predefined subunit composition and arrangement as tools for the development of novel selective pharmacological and therapeutic agents.


The Cys-loop ligand-gated ion channel (LGIC) family is a group of neurotransmitter receptors that are involved in fast synaptic transmission and includes the muscle and neuronal nicotinic acetylcholine receptors (AChR), the serotonin type 3 receptor, the GABAA receptor (GABAAR), and the glycine receptor (Connolly and Wafford, 2004Go; Lester et al., 2004Go). All members of the LGIC family are believed to be pentameric in structure, with one or more different homologous subunits arranged around a central pore that forms the channel itself. Binding of the appropriate agonist to the receptor induces a conformational change in the protein, resulting in the opening of the ion channel, and initiating the sequelae of channel activation.

So far, a large number of subunits for each type of LGIC have been cloned (Table 1), and many studies have been carried out using heterologous expression systems such as Xenopus laevis oocytes or transfected mammalian cells to understand how subunit composition affects the functional properties of the receptor. For example, coexpression of the GABAAR {alpha}1 and beta1 subunits in human embryonic kidney 293 cells results in receptors that display much of the pharmacology of bona fide GABAARs, including potentiation by barbiturates, but these receptors are insensitive to benzodiazepines. However, coexpression of the {gamma}2 subunit with the {alpha}1 and beta1 subunits produces receptors with benzodiazepine binding sites and functional responses to benzodiazepines (Pritchett et al., 1989Go), demonstrating the crucial role that {gamma} subunits play in GABAAR function.


View this table:
[in this window]
[in a new window]
 
TABLE 1 Human LGIC subunit genes/gene products

Various human genes/gene products for each receptor cloned to date and listed in the current version of the ligand-gated ion channel database [http://www.ebi.ac.uk/compneur-srv/LGICdb/LGICdb.php (Le Novere and Changeux, 2001Go)]. Please note that not all of the gene products have been unequivocally demonstrated to be incorporated into LGICs in vivo.

 

An equally important goal of the expression studies is to duplicate various receptor subunit combinations found in vivo to use these refined systems as tools for developing receptor (sub)subtype-selective pharmacological agents. These tools could then be used not only for analysis of the properties of receptors themselves but also for the development of novel therapeutic agents targeted toward a specific receptor (sub)subtype (Gotti et al., 2000Go; Bunnelle et al., 2004Go). However, for this approach to be truly fruitful, one must first determine the subunit stoichiometry of a given target and then develop methods for the expression of receptors with this exact stoichiometry and subunit arrangement. Neither of these tasks is by any means easy or straightforward.

Consider the simplest nontrivial situation—a pentameric receptor that contains two different subunits, A and B. There are six possible subunit stoichiometries (A5,A4B, A3B2,A2B3, AB4, and B5). With identical handedness governed by l-amino acid chirality, there are eight possible unique subunit arrangements in the complex (Fig. 1). In the absence of a detailed understanding of the "rules" for receptor assembly, it is not possible a priori to predict the exact subunit stoichiometry and/or subunit arrangement in the complex when two different types of subunits could be incorporated into the complex. When there are more than two different subunits that could potentially be incorporated into the receptor (as is more often the case; see Table 1), the situation becomes even more complex. In either situation, experimental techniques must be developed to address the issue of subunit stoichiometry and subunit arrangement.


Figure 1
View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1. Possible subunit stoichiometries and spatial arrangement of a receptor containing five subunits, each of which can be either an "A" subunit or a "B" subunit. Note that even for this simple system, there are six possible stoichiometries and eight potential arrangements of the subunits in the pentamer.

 
In the case of naturally occurring receptors, subunit-specific antibodies have been used to determine subunit stoichiometry (but not arrangement) from tissue homogenates (Benke et al., 1996Go; Li and De Blas, 1997Go; Turner and Kellar, 2005Go). Although this approach can certainly determine which subunits are associated with each other in a complex, it may not be able to identify all complexes that occur naturally because of the sensitivity of detection methods and may not be quantitative enough to unambiguously determine subunit stoichiometry. Nonetheless, studies of this type have identified a number of potential subunit combinations and stoichiometries of naturally occurring receptors, and provide the groundwork for studies in heterologous expression systems using more defined subunit composition.

Heterologous expression systems, such as X. laevis oocytes or transfected mammalian cells, have been used to determine subunit stoichiometry and to create receptors of defined subunit composition by introducing RNA or DNA for one or more subunits. Subunit stoichiometry can then be determined by analyzing the properties of the expressed receptors using a variety of techniques, including immunoprecipitation with subunit-selective antisera (Anand et al., 1991Go; Kellenberger et al., 1996Go; Knight et al., 2000Go), analysis of the effects of mutations in the pore-forming domain that alter receptor properties (Cooper et al., 1991Go; Backus et al., 1993Go; Chang et al., 1996Go; Boorman et al., 2000Go; Burzomato et al., 2003Go), and, in one case, atomic force microscopy (Barrera et al., 2005Go). Studies such as these provide most of what we know about subunit stoichiometry of receptors containing various subunits.

However, although one assumes/hopes that the receptors expressed in these systems will be faithful surrogates for naturally occurring receptors, there is some evidence that in heterologous expression systems, the ratio of subunits in a given receptor complex depends on the ratios of exogenous subunit RNA or DNA introduced into the expression system, resulting in variable subunit stoichiometry (Hedblom and Kirkness, 1997Go; Zwart and Vijverberg, 1998Go; Nelson et al., 2003Go). In addition, it is clear that these systems can produce receptors that probably do not exist in vivo—either homomeric receptors (Beato et al., 2002Go) or subunit-deficient complexes (Jackson et al., 1990Go; Charnet et al., 1992Go). Furthermore, the presence of endogenous subunits in the expression system may further complicate the analysis of the effects of altering subunit composition on receptor function (Buller and White, 1990Go). Therefore, these systems may not always produce the type of receptors expected, and conclusions obtained from such studies may not be as firm as one would like.

One method to obtain the expression of receptors of known/predefined subunit stoichiometry and even subunit orientation is the use of concatameric subunit constructs. This forces subunits to be in a particular stoichiometry and spatial arrangement by expressing a polyprotein containing more than one subunit sequences in the mature protein. This is essentially what is seen naturally in some voltage-gated channels. In the case of K+ channels, the channel is a true tetramer formed from four individual subunits (MacKinnon, 1991Go; Doyle et al., 1998Go), whereas in Na+ and Ca2+ channels, the "tetramer" is formed by four homologous repeat domains within a single large polypeptide chain encoding the main subunit (Catterall, 1995Go).

Originally applied to voltage-gated K+ channels (Liman et al., 1992Go), this approach has been used for several members of the LGIC family (Im et al., 1995Go; Baumann et al., 2001Go; Zhou et al., 2003Go; Grudzinska et al., 2005Go). In most cases, tandem dimeric subunits were created with a polyglutamine linker containing 10 to 25 glutamines between the two subunits. At this length, polyglutamine is water-soluble and assumes a random coil conformation (Altschuler et al., 1997Go), making it an ideal linker for this purpose. Expression of the dimeric construct with one or more individual subunits can then be used to determine not only the subunit stoichiometry but also the spatial arrangement of the subunits in the complex. For example, if expression of A->B tandem subunits (where the carboxyl terminus of the A subunit is joined to the amino terminus of the B subunit via the linker) alone does not produce functional receptors, then one can rule out dimers, tetramers, or hexamers as forming the entire receptor complex (which would not be surprising given the fact that numerous studies analyzing receptors from both tissues and heterologous systems have demonstrated that these receptors are pentamers). If coexpression of the A->B dimer with the B subunit formed functional receptors but coexpression of A subunit with the dimer did not, then (assuming a pentameric complex) one would conclude that the stoichiometry of the receptor was A2B3 and the subunit arrangement in the complex was A->B->A->B->B (and then back to the initial "A" in the sequence to complete the loop).

The above analysis assumes that both parts of the dimeric subunit are incorporated into the same receptor complex. However, two recent studies suggest that this may not always be the case, complicating the analysis of the results. Through the use of {alpha}4->beta2 and beta2->{alpha}4 nicotinic AChR receptor subunit dimer constructs, Zhou et al. (2003Go) showed that in some cases, the subunits in the dimer may be incorporated into two separate complexes, resulting in a dimer of pentameric complexes held together by the linker. Groot-Kormelink et al. (2004Go) used a wide variety of dimers containing various {alpha}-subunits of neuronal AChRs combined with various beta-subunits in both orientations (i.e., {alpha}->beta and beta->{alpha}) and analyzed the properties of the expressed receptors. Surprisingly, they found that some dimer constructs expressed alone in X. laevis oocytes gave rise to functional receptors, which is at odds with the known pentameric structure of the receptor. Further analysis using mutations in the beta subunit led the authors to conclude that in some cases, only one subunit in the dimer was incorporated into the complex, with the remaining subunit "floating in the wind" as an appendage outside of the complex.

These two studies demonstrate that the use of tandem dimeric subunits is not as clean as originally anticipated, and set the groundwork for the study by Groot-Kormelink et al. (2006Go) in the current issue. In this work, the authors expressed not tandem dimers, but concatameric pentamers containing {alpha}3 and beta4 nicotinic AChR subunits in the order beta4->beta4->{alpha}3->beta4->{alpha}3 and compared the functional properties of these receptors with those expressed from the monomeric {alpha}3 and beta4 subunits together. The functional properties of the receptors expressed from the pentameric construct were essentially identical to those expressed from the monomers. Through the coexpression of {alpha}3 or beta4 subunits with a mutation in the pore domain that alters channel gating (L9'T; Revah et al., 1991Go; Filatov and White, 1995Go; Labarca et al., 1995Go) as a probe for incorporation of monomeric subunits, the authors were able to rule out proteolytic breakdown of the pentameric construct and subsequent reincorporation of monomeric subunits into the complex. Thus, the pentameric construct produces a fully functional receptor.

In a demonstration of the usefulness of this technique, the authors constructed a receptor in which only one of the two {alpha}3 subunits in the complex contained the L9'T mutation. Previous work suggested that when multiple subunits contained this change that the mutation in each subunit made more or less equal contributions to the overall change in receptor gating (Filatov and White, 1995Go; Labarca et al., 1995Go). However, because it was not possible in the original studies to ensure that only a single mutant {alpha} subunit was incorporated into the complex, this notion could not be tested in an unambiguous fashion. In the present study, the authors were able to ensure incorporation of a single mutant {alpha}3 subunit into the receptor, leaving the other {alpha}3 subunit as a wild type, and they found that mutations in each subunit did not produce equivalent effects. This type of experiment could never be carried out without the use of the pentameric constructs.

Although this study provides interesting AChR-specific findings as well as a general approach that should be applicable to other LGICs, two types of additional experiments should be carried out before this method is elevated to panacea status. First, do other linear sequences that should produce the same arrangement of subunits in the complex (e.g., {alpha}3->beta4->beta4->{alpha}3->beta4) give the same results? One might expect that they would, but it would be nice to demonstrate this. If the alternate sequences do not result in the formation of functional receptors, this might provide an opening to a more detailed analysis of the contributions of particular regions of each subunit that contribute to the subunit-subunit interactions that hold the complex together. Second, do other subunit arrangements (e.g., beta4->beta4->beta4->{alpha}3->{alpha}3) not produce functional receptors? If the receptor has a unique stoichiometry and subunit arrangement, concatamers such as this should not work. If other constructs do work, it would demonstrate that there is not a unique arrangement of a given group of subunits and lays the groundwork for future studies of how subunit arrangement affects receptor function.

The construction of pentameric subunit concatamers now allows several types of studies that could not be carried out before. First, as demonstrated in this study, one can incorporate a mutation into just one subunit of the receptor to examine the role of individual subunits—even those that may be present in multiple copies in the complex. Although one might consider this a situation that would occur only in experiments designed to probe receptor structure-function relationships, this also might be observed in the case of polymorphisms in heterozygotes for a particular mutation. Application of this approach to the ligand-binding site regions [which are believed to be located at subunit-subunit interfaces (Karlin, 2004Go)] should allow the delineation of the role of residues on either half of a specific ligand-binding site in the receptor in the actions of agonists and antagonists. Second, and perhaps of much wider interest, one can now create receptors of predefined subunit stoichiometry and arrangement and use these not only to test which stoichiometries/arrangements produce functional receptors but also to create well defined targets for the development of novel experimental probes and therapeutic agents with receptor (sub)subtype selectivity. It is now time for the fun stuff to begin!


    Footnotes
 
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

doi:10.1124/mol.105.020727.

Please see the related article on page 559

ABBREVIATIONS: LGIC, Cys-loop ligand gated ion channel; AChR, nicotinic acetylcholine receptor; GABAAR, GABAA receptor.

Address correspondence to: Dr. Michael M. White, Department of Pharmacology and Physiology, Drexel University College of Medicine, 245 N. 15th Street, Philadelphia, PA 19102. E-mail: mikewhite{at}drexel.edu


    References
 Top
 Abstract
 References
 
Altschuler E, Hud N, Mazrimas J, and Rupp B (1997) Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res 50: 73–75.[Medline]

Anand R, Conroy W, Schoepfer R, Whiting P, and Lindstrom J (1991) Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biol Chem 266: 11192–11198.[Abstract/Free Full Text]

Backus K, Arigoni M, Drescher U, Scheurer L, Malherbe P, Mohler H, and Benson J (1993) Stoichiometry of a recombinant GABAA receptor deduced from mutation-induced rectification. Neuroreport 13: 285–288.

Barrera N, Herbert P, Henderson R, Martin I, and Edwardson J (2005) Atomic force microscopy reveals the stoichiometry and subunit arrangement of 5-HT3 receptors. Proc Natl Acad Sci USA 102: 12595–12600.[Abstract/Free Full Text]

Baumann S, Baur R, and Sigel E (2001) Subunit arrangement of {gamma}-aminobutyric acid type A receptors. J Biol Chem 276: 36275–36280.[Abstract/Free Full Text]

Beato M, Groot-Kormelink P, Colquhoun D, and Sivilotti L (2002) Openings of rat recombinant {alpha}1 homomeric glycine receptor as a function of the number of agonist molecules bound. J Gen Physiol 119: 443–466.[Abstract/Free Full Text]

Benke D, Honer M, Michel C, and Mohler H (1996) GABAA receptor subtypes differentiated by their gamma-subunit variants: prevalence, pharmacology and subunit architecture. Neuropharmacology 35: 1413–1423.[CrossRef][Medline]

Boorman J, Groot-Koremlinnk P, and Sivilotti L (2000) Stoichiometry of human recombinant neuronal nicotinic receptors containing the beta3 subunit expresed in Xenopus oocytes. J Physiol 529: 565–577.[Abstract/Free Full Text]

Buller A and White M (1990) Functional acetylcholine receptors expressed in Xenopus oocytes after injection of Torpedo beta, {gamma}, and {delta} subunit RNAs are a consequence of endogenous gene expression. Mol Pharmacol 37: 423–428.[Abstract]

Bunnelle W, Dart M, and Schrimpf M (2004) Design of ligands for nicotinic acetylcholine receptors: The quest for selectivity. Curr Top Med Chem 4: 299–334.[CrossRef][Medline]

Burzomato V, Groot-Koremlinnk P, Sivilotti L, and Beato M (2003) Stoichiometry of recombinant heteromeric glycine receptors revealed by a pore-lining region point mutation. Recept Channels 9: 353–361.[Medline]

Catterall W (1995) Structure and function of voltage-gated ion channels. Annu Rev Biochem 64: 493–531.[CrossRef][Medline]

Chang Y, Wang R, Barot S, and Weiss D (1996) Stoichiometry of a recombinant GABAA receptor. J Neurosci 16: 5415–5424.[Abstract/Free Full Text]

Charnet P, Labarca C, and Lester H (1992) Structure of the {gamma}-less nicotinic acetylcholine receptor: Learning from omission. Mol Pharmacol 41: 708–717.[Abstract]

Connolly C and Wafford K (2004) The cys-loop superfamily of ligand-gated ion channels; The impact of receptor structure on function. Biochem Soc Trans 32: 529–534.[CrossRef][Medline]

Cooper E, Couturier S, and Ballivet M (1991) Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature (Lond) 350: 235–238.[CrossRef][Medline]

Doyle D, Cabral J, Pfuetzner R, Kuo A, Galbis J, Cohen S, Chait B, and MacKinnon R (1998) The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science (Wash DC) 280: 69–77.[Abstract/Free Full Text]

Filatov G and White M (1995) The role of conserved leucines in the M2 domain of the acetylcholine receptor in channel gating. Mol Pharmacol 48: 379–384.[Abstract]

Gotti C, Carbonnelle E, Moretti M, Zwart R, and Clementi F (2000) Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? Behav Brain Res 113: 183–192.[CrossRef][Medline]

Groot-Kormelink P, Broadbent S, Beato M, and Sivilotti L (2006) Constraining the expression of nicotinic acetylcholine receptors by using pentameric constructs. Mol Pharmacol 69: 559–564.

Groot-Kormelink P, Broadbent S, Boorman J, and Sivilotti L (2004) Incomplete incorporation of tandem subunits in recombinant neuronal nicotinic receptors. J Gen Physiol 123: 697–708.[Abstract/Free Full Text]

Grudzinska J, Schemm R, Haeger S, Nicke A, Schmalzing G, Betz H, and Laube B (2005) The beta subunit determines the ligand-binding properties of synaptic glycine receptors. Neuron 45: 727–739.[CrossRef][Medline]

Hedblom E and Kirkness E (1997) A novel class of GABAA receptor in tissues of the reproductive system. J Biol Chem 272: 15346–15350.[Abstract/Free Full Text]

Im WB, Pregenzer JF, Binder JA, Dillon GH, and Alberts GL (1995) Chloride channel expression with the tandem construct of {alpha}6-beta2 GABAA receptor subunit requires a monomeric subunit of {alpha}6 or {gamma}2. J Biol Chem 20: 26063–26066.

Jackson M, Imoto K, Mishina M, Konno T, Numa S, and Sakmann B (1990) Spontaneous and agonist-induced openings of an acetylcholine receptor channel composed of bovine muscle {alpha}-, beta- and {delta}-subunits. Pflueg Arch Eur J Physiol 417: 129–135.[CrossRef][Medline]

Karlin A (2004) A touching picture of nicotinic binding. Neuron 41: 841–842.[CrossRef][Medline]

Kellenberger S, Eckenstein S, Bauer R, Malherbe P, Buhr A, and Sigel E (1996) Subunit stoichiometry of oligomeric membrane proteins: GABAA receptors isolated by selective immunoprecipitation from the cell surface. Neuropharmacology 35: 1403–1411.[CrossRef][Medline]

Knight A, Stephenson F, Talman J, and Ramabahdran T (2000) Monospecific antibodies as probes for the stoichiometry of recombinant GABAA receptors. Recept Channels 7: 213–226.[Medline]

Labarca C, Nowak M, Zhang H, Tang L, Deshpande P, and Lester H (1995) Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. Nature (Lond) 376: 514–516.[CrossRef][Medline]

Le Novere N and Changeux J-P (2001) LGICdb: the ligand-gated ion channel database. Nuc Acids Res 29: 294–295.[Abstract/Free Full Text]

Lester H, Dibas M, Dahan D, Leite J, and Dougherty D (2004) Cys-loop receptors: new twists and turns. Trends Neurosci 27: 329–336.[CrossRef][Medline]

Li M and De Blas A (1997) Coexistence of two beta subunit isoforms in the same {gamma}-aminobutyric acid type A receptor. J Biol Chem 272: 16564–16569.[Abstract/Free Full Text]

Liman E, Tytgat J, and Hess P (1992) Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs. Neuron 9: 861–871.[CrossRef][Medline]

MacKinnon R (1991) Determination of the subunit stoichiometry of a voltage-activated potassium channel. Nature (Lond) 350: 232–235.[CrossRef][Medline]

Nelson M, Kuryatov A, Choi C, Zhou Y, and Lindstrom J (2003) Alternate stoichiometries of {alpha}4beta2 nicotinic acetylcholine receptors. Mol Pharmacol 63: 332–341.[Abstract/Free Full Text]

Pritchett D, Sontheimer H, Shivers B, Ymer S, Kettenmann H, Schofield P, and Seeburg P (1989) Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature (Lond) 338: 582–585.[CrossRef][Medline]

Revah F, Bertrand D, Galzi J-L, Devillers-Thiery A, Mulle C, Hussy N, Bertrand S, Ballivet M, and Changeux J-P (1991) Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature (Lond) 353: 846–849.[CrossRef][Medline]

Turner J and Kellar K (2005) Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes. J Neurosci 25: 9258–9265.[Abstract/Free Full Text]

Zhou Y, Nelson M, Kuryatov A, Choi C, Cooper J, and Lindstrom J (2003) Human {alpha}4beta2 acetylcholine receptors formed from linked subunits. J Neurosci 23: 9004–9015.[Abstract/Free Full Text]

Zwart R and Vijverberg H (1998) Four pharmacologically distinct subtypes of {alpha}4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes. Mol Pharmacol 54: 1124–1131.[Abstract/Free Full Text]


Related articles in MolPharm:

Constraining the Expression of Nicotinic Acetylcholine Receptors by Using Pentameric Constructs
Paul J. Groot-Kormelink, Steven Broadbent, Marco Beato, and Lucia G. Sivilotti
MolPharm 2006 69: 558-563. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
JGPHome page
J. T. Sack, O. Shamotienko, and J. O. Dolly
How to Validate a Heteromeric Ion Channel Drug Target: Assessing Proper Expression of Concatenated Subunits
J. Gen. Physiol., May 1, 2008; 131(5): 415 - 420.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.105.020727v1
69/2/407    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, M. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYSTEINE


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics